Prolactin involvement in breast cancer.
Normal development and differentiation of the mammary gland are profoundly influenced by prolactin (PRL). In rodent mammary cancer PRL plays a well defined role, but its role, in human breast cancer has not been appreciated until recently. It is now clear that breast tissue, both normal and malignant, is a significant source of extrapituitary PRL. Thus an autocrine/paracrine role of PRL in human breast cancer may be invoked. Both PRL and PRL receptor mRNA are expressed in the vast majority of breast cancer biopsies independent of estrogen and progesterone receptor status. An autocrine/paracrine PRL acting in human breast cancer requires that this hormone's action be blocked at the cellular level, as opposed to suppressing the synthesis and secretion of pituitary PRL. Mutants of PRL or human growth hormone are being explored which act as selective PRL antagonists. In addition, tamoxifen has been shown to act locally at the target tissue by binding directly to the PRL receptor and thus inhibiting PRL's action. These strategies may have clinical relevance in treating PRL-responsive human breast cancer.
Vonderhaar
B K
BK
Molecular and Cellular Endocrinology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1402, USA.
D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000503:physiopathology; D011388:Prolactin / Q000235:genetics / Q000502:physiology*; D011981:Receptors, Prolactin / Q000235:genetics / Q000502:physiology*
D011981:Receptors, Prolactin; D011388:Prolactin